Trade Summary

4 days ago, Albers Jeffrey W., serving as Dir at Spyre Therapeutics, Inc. (SYRE), sold 23,000 shares at $104.53 per share, for a total transaction value of $2,404,190.00. Following this transaction, Albers Jeffrey W. now holds 9,360 shares of SYRE.

This sale represents a 71.08% decrease in Albers Jeffrey W.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, August 7, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, August 11, 2026 (accepted Aug 10, 9:31 PM ET), 4 days after the trade was made.

Spyre Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.